IMMUNE RESPONSE CORPORATION MOVES FORWARD WITH HIV DRUG TRIAL

A A

The Immune Response Corporation has completed the first stage of enrollment of drug-naive HIV patients in a Phase II clinical study being conducted in Italy.

The study, which has enrolled a total of 31 returning patients from a previous trial and 54 new patients, will examine IR103, a second generation immunotherapy, as a first-line treatment for drug-naive HIV-infected individuals not yet recommended for antiretroviral therapy according to current medical guidelines. In addition, approval has been obtained for expansion of the study to include an additional 50 patients, and enrollment of the additional patients has begun. Ultimately over 200 drug-naive patients will be enrolled in two parallel studies with sites in Italy, France, Canada and the UK.